HOTH Stock | | | USD 0.85 0.01 1.16% |
This module uses fundamental data of Hoth Therapeutics to approximate its Piotroski F score. Hoth Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Hoth Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Hoth Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
Hoth Therapeutics Altman Z Score,
Hoth Therapeutics Correlation,
Hoth Therapeutics Valuation, as well as analyze
Hoth Therapeutics Alpha and Beta and
Hoth Therapeutics Hype Analysis.
For more detail on how to invest in Hoth Stock please use our
How to Invest in Hoth Therapeutics guide.
The Hoth Therapeutics' current
Net Debt To EBITDA is estimated to increase to 57.00, while
Net Debt is forecasted to increase to (8.8
M). As of now, Hoth Therapeutics'
EV To Free Cash Flow is increasing as compared to previous years. The Hoth Therapeutics' current
Net Debt To EBITDA is estimated to increase to 57.00, while
PTB Ratio is projected to decrease to 0.53.
At this time, it appears that Hoth Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Current Return On Assets | Negative | Focus |
| Change in Return on Assets | Decreased | Focus |
| Cash Flow Return on Assets | Negative | Focus |
| Current Quality of Earnings (accrual) | Decreasing | Focus |
| Asset Turnover Growth | No Change | Focus |
| Current Ratio Change | Decrease | Focus |
| Long Term Debt Over Assets Change | N/A | Focus |
| Change In Outstending Shares | Decrease | Focus |
| Change in Gross Margin | No Change | Focus |
Hoth Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Hoth Therapeutics is to make sure Hoth is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Hoth Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Hoth Therapeutics' financial numbers are properly reported.
Hoth Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Hoth Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Hoth Therapeutics in a much-optimized way.
Click cells to compare fundamentals
About Hoth Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Hoth Therapeutics
offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics'
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock: Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share | Return On Assets | Return On Equity |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine
if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.